Drug Profile
Berdazimer sodium - SB 414 - Novan Inc
Alternative Names: MAP3-NONOate - SB-414; NVN1000-SB414; SB-414Latest Information Update: 17 May 2021
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Novan Inc
- Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Free radicals; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Atopic dermatitis; Psoriasis